BERKELEY, Calif. (AP) _ Aduro Biotech Inc. (ADRO) on Wednesday reported a fourth-quarter loss of $29.6 million, after reporting a profit in the same period a year earlier.
On a per-share basis, the Berkeley, California-based company said it had a loss of 44 cents.
The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 38 cents per share.
The drug developer posted revenue of $3.9 million in the period, beating Street forecasts. Three analysts surveyed by Zacks expected $3.8 million.
For the year, the company reported that its loss widened to $91.1 million, or $1.40 per share. Revenue was reported as $50.7 million.
Aduro Biotech shares have declined slightly more than 1 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $11.25, a decline of 30 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ADRO at https://www.zacks.com/ap/ADRO
Keywords: Aduro Biotech, Earnings Report